Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -700.1%. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $2M | $889226 | — | — | — |
| Enterprise Value | $2M | $1M | — | — | — |
| P/E Ratio → | -0.27 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 1.40 | 0.75 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -700.1% | -700.1% | -80.8% | -54.3% | -108.1% |
| ROA | -264.5% | -264.5% | -29.9% | -33.4% | -106.5% |
| ROIC | -242.3% | -242.3% | -21.1% | -27.1% | — |
| ROCE | -622.0% | -622.0% | -72.1% | -52.1% | -108.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 2.57 | 1.14 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | 0.18 | 2.56 | 1.08 | -0.29 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -15.54 | -15.54 | -8.28 | -23.57 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 0.13 | 0.13 | 0.00 | 0.24 | 20.12 |
| Quick Ratio | 0.13 | 0.13 | 0.00 | 0.24 | 20.12 |
| Cash Ratio | 0.05 | 0.05 | 0.00 | 0.06 | 19.88 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 7.2% | 13.5% | — | — | — |
| Total Shareholder Yield | 7.2% | 13.5% | — | — | — |
| Shares Outstanding | — | $19M | $19M | $19M | $19M |
Imminent liquidity and dilution
As reported in financial statements, Klotho Neurosciences has consistently posted negative ROIC figures, reaching -57.9% in 2025Q3, which underscores the company's inability to generate productive returns on invested capital while it remains in a pre-revenue, research-heavy phase of its corporate development cycle.
The persistent decay in ROIC, which hit a low of -139.1% in 2024Q3, reflects the high cost of capital deployment into preclinical gene therapy assets that have yet to reach commercial viability. Investors should interpret these figures as evidence that the company is currently destroying shareholder value through capital consumption rather than compounding it through operational efficiency.
Based on recent SEC filings, the company's current ratio of 83.69 in 2025Q3 appears deceptively high, yet this metric is heavily distorted by the timing of capital raises and does not reflect the underlying reality of a business with minimal cash reserves relative to its burn rate.
While the quick ratio mirrors the current ratio, suggesting a lack of inventory dependence, the extreme volatility in these metrics over the last ten quarters indicates a reliance on episodic financing. This liquidity profile warrants further investigation, as it suggests the company may face significant operational stress if it cannot secure additional funding to cover its ongoing research obligations.
According to market data, KLTOW trades at a P/B of 1.40, which, when compared to peers like AC Immune S.A. at 4.65, suggests that the market is applying a significant discount to the company's book value due to its precarious cash position and early-stage clinical profile.
The gap between KLTOW and its peers appears structural rather than temporary, as the market likely prices in the high probability of future dilutive equity offerings. This valuation suggests that investors are viewing the company more as a distressed asset than a standard clinical-stage biotechnology firm.
The price-to-book ratio is the most commonly misapplied metric for KLTOW, as it obscures the fact that a significant portion of the company's book value is comprised of intangible assets and goodwill rather than tangible, liquid resources available to support ongoing research and development activities.
Analysts should instead focus on the cash-to-burn ratio or the projected runway, as book value provides a false sense of security in a pre-revenue entity. Relying on P/B ignores the reality that the company's primary assets are intellectual property that may hold little liquidation value in the event of a funding shortfall.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KLTOW stock.
Klotho Neurosciences, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Klotho Neurosciences, Inc.'s return on equity (ROE) is -700.1%. The historical average is -81.0%.
Based on historical data, Klotho Neurosciences, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.